Haploidentical PBMC Transplant for Severe Congenital Anemias

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2009

Primary Completion Date

August 1, 2018

Study Completion Date

September 10, 2026

Conditions

Sickle Cell Anemia

Interventions

PROCEDURE

PBSC Transplant

PBSC transplant

DRUG

Alemtuzumab

alemtuzumab

DRUG

Sirolimus

sirolimus

DRUG

Cyclophosphamide

cyclophosphamide

PROCEDURE

Low Dose Irradiation

low dose irradiation

Trial Locations (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00977691 - Haploidentical PBMC Transplant for Severe Congenital Anemias | Biotech Hunter | Biotech Hunter